• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Neuropathology: official journal of the Japanese Society of Neuropathology >Carbonic anhydrase IX is a prognostic biomarker in glioblastoma multiforme
【24h】

Carbonic anhydrase IX is a prognostic biomarker in glioblastoma multiforme

机译：碳酸酐酶IX是胶质母细胞瘤多形形的预后生物标志物

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The identification of prognostic factors in patients with glioblastoma multiforme (GBM) represents an area of increasing interest. Carbonic anhydrase IX (CA‐IX), a hypoxia marker, correlates with tumor progression in a variety of human cancers. However, the role of CA‐IX in GBM remains largely unknown. In the present study, we evaluated the prognostic role of CA‐IX in GBM patients. In total, 66 consecutive patients with GBM who received concomitant chemoradiotherapy and adjuvant chemotherapy with temozolomide were retrospectively reviewed, and all patients received temozolomide chemotherapy for at least 3?months. Kaplan–Meier curves and log‐rank tests were used for analysis of progression‐free survival (PFS) and overall survival (OS), and a multivariate Cox proportional hazard model was employed to identify factors with an independent effect on survival. The median OS was longer in patients with low levels of CA‐IX expression (18?months) compared to patients overexpressing CA‐IX (9?months) ( P ?=?0.004). There was not a statistically significant difference in median PFS (3.5 vs. 8?months, P ?=?0.054) between patients with high or low levels of CA‐IX expression. In multivariate analysis, the variables that were identified as significant prognostic factors for OS were preoperative Karnofsky performance scale score (KPS) (hazard ratio (HR), 3.703; P ?=?0.001), CA‐IX overexpression (HR, 1.967; P ?=?0.019), and incomplete adjuvant temozolomide treatment (HR, 2.241; P ?=?0.003) and gross‐total resection (HR, 1.956; P ?=?0.034). Our findings indicated that CA‐IX may be a potential prognostic biomarker in the treatment of GBM.
机译：鉴定胶质母细胞瘤多形态（GBM）的预后因子代表了越来越多的兴趣区域。碳酸酐酶IX（Ca-IX），一种缺氧标志物，与各种人类癌症中的肿瘤进展相关。然而，CA-IX在GBM中的作用仍然很大程度上是未知的。在本研究中，我们评估了CA-IX在GBM患者中的预后作用。回顾性地评估了总共66名接受伴随的化学疗法和佐剂化疗的GBM患者，所有患者均接受替莫唑胺化疗至少3？数月。 Kaplan-Meier曲线和对数级测试用于分析无进展生存（PFS）和总体存活（OS），并且使用多元COX比例危险模型来识别对生存的独立影响的因素。与过表达CA-IX（9？月）过表达的患者（9？= 0.004）相比，中位操作系统更长的Ca-IX表达（18？月）患者较长。在CA-IX表达的高或低水平的患者之间，中位数PFS（3.5与8？月，P？= 0.054）没有统计学上显着差异。在多变量分析中，被鉴定为OS的显着预后因子的变量是术前Karnofsky性能尺度评分（KPS）（危险比（HR），3.703; P？= 0.001），Ca-IX过度表达（HR，1.967; P. ？=？0.019）和不完全的佐剂替莫唑胺治疗（HR，2.241; p？= 0.003）和总切除总体切除（HR，1.956; p？= 0.034）。我们的研究结果表明，CA-IX可能是治疗GBM的潜在预后生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号